Alkermes plc. (ALKS) stock: key figures, P/E, revenue and dividend
Health Care · Ireland · ISIN USG017671052
Alkermes plc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 1.48 bn USD |
| Gross profit | 1.28 bn USD |
| Operating income | 253.96 m USD |
| EBIT | 258.42 m USD |
| Net income | 241.66 m USD |
| Diluted EPS – continuing operations | 1.43 USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Alkermes plc.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
More stocks
- Hitachi Construction Machinery Co Ltd (6305.T)
- STIFEL FINANCIAL CORP (SF)
- Hims & Hers Health, Inc. (HIMS)
- Praxis Precision Medicines, Inc. (PRAX)
- Figma, Inc. (FIG)
- Gotion High tech Co Ltd (002074.SZ)
- Jiujiang Defu Technology Co Ltd Ordinary Shares - Class A (301511.SZ)
- Gigabyte Technology Co Ltd (2376.TW)
- MERLIN Properties SOCIMI SA (MRL.MC)
- Simpson Manufacturing Co., Inc. (SSD)
- Grupo Aeroportuario del Sureste S. A. B. de C. V (ASURB.MX)
- Sysmex Corp (6869.T)
Not investment advice. All data without warranty, price as of 19.10.2026. Details in the risk notice.